A., Teras, L. R., Terry, M. B., Torres, D., Troester, M. A., Vachon, C. M., van Deurzen, C. H., van Veen, E. M., Wagner, P., Weinberg, C. R., Wendt, C., Wesseling, J., Winqvist, R., Wolk, A., Yang, X. R., Zheng, W., Couch, F. J., Simard, J., Kraft, P., Easton, D. F., Pharoah, P. D., Schmidt, M. K., Garca-Closas, M., Chatterjee, N. Genetic Insights Into Biological Mechanisms Governing Human Ovarian Ageing, Multicancer hereditary syndrome testing: Genetic counselors' perspectives. Private insurance status was associated with higher odds of 21-gene assay uptake (Medicaid vs private insurance: adjusted odds ratio, 0.86; P=.02), and high area-level SES was associated with an increased odds of uptake (quintile 5 vs 1: adjusted odds ratio, 1.6; P Women with BRCA1/2 mutations inherit high risks of breast and ovarian cancer; options to reduce cancer mortality include prophylactic surgery or breast screening, but their efficacy has never been empirically compared. Methods of direct contact included telephone calls, letters, and e-mails; respective rates of genetic testing completion were 61% (95% CI, 51 to 70), 48% (95% CI, 37 to 59), and 48% (95% CI, 45 to 50).Most relatives at risk for hereditary cancer do not undergo cascade genetic counseling and testing, forgoing potentially life-saving medical interventions. This multi-institutional, multidisciplinary approach may be useful for organizations to frame responses as similar legislation is passed across the United States. The coefficient of variation (CV) and intraclass coefficient (ICC) were estimated using the random effect model.Reproducibility for the assay was satisfactory, with a CV of 11.2% and an ICC of 98.9%; correlation between the replicate samples was also high (R = 0.96). There are concerns that multigene panel testing compared with BRCA1/ 2-only testing after diagnosis of breast cancer may lead to unnecessary patient worry about cancer because of more ambiguous results.Patients with breast cancer diagnosed from 2013 to 2015 and accrued from SEER registries in Georgia and Los Angeles were surveyed (n = 5,080; response rate, 70%), and responses were merged with SEER data and germline genetic testing and results. Patients were accrued from September 2001 to May 2003. On the other hand, her now ex-husband Corey is the son of Rick Harrison and his ex-wife, Kim Harrison. The goals of the current study were to characterize further the relation of histologic-specific ovarian cancer risks to reproductive and lifestyle attributes.The authors conducted a pooled analysis of 10 case-control studies of ovarian cancer in US White women, involving 1834 patients with invasive epithelial ovarian cancer (1067 serous, 254 mucinous, 373 endometrioid, and 140 clear cell) and 7484 control women.Risks of all four histological types were inversely associated with parity and oral contraceptive use, but the histologic types showed different associations with nonreproductive factors. of pertuzumab given in combination with trastuzumab (Herceptin) and vinorelbine in first line Clinical guidelines for high-risk women should consider integrating shared decision making for risk-reducing medication and screening on the basis of individual risk factors. Identification of germline variants associated with survival in aggressive types of breast cancer may inform understanding of breast cancer progression and assist treatment. These may be useful in the patient's decision-making process and impact uptake of risk-management options. Schackmann, E. A., Vinayak, S., Kurian, A. W., et al. Surveys were sent approximately 2 months after surgery. To reduce the barrier of testing, a multiplex SNaPshot genotyping panel that targeted 25 ChineseBRCA1/2mutation hotspots was developed, and its feasibility was evaluated in a local cohort of 441 breast and 155 ovarian cancer patients. The mean accuracy of the NLP model for detecting any site of distant recurrence was 0.9 for breast cancer and 0.83 for HCC. Afghahi, A., Purington, N., Han, S. S., Desai, M., Pierson, E., Mathur, M. B., Seto, T., Thompson, C. A., Rigdon, J., Telli, M. L., Badve, S. S., Curtis, C. N., West, R. B., Horst, K., Gomez, S. L., Ford, J. M., Sledge, G. W., Kurian, A. W. Genetic testing and results in population-based breast cancer patients and ovarian cancer patients. View details for Web of Science ID 000863680300121, View details for Web of Science ID 000863680301817, View details for Web of Science ID 000863680302515, View details for Web of Science ID 000863680301695, View details for Web of Science ID 000863680300063, View details for Web of Science ID 000863680300130, View details for Web of Science ID 000863680300138, View details for Web of Science ID 000863680300221, View details for Web of Science ID 000863680300131, View details for Web of Science ID 000863680303824. Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings. HER2-positive breast cancer varies less by race (1.56-1.91%). Both HOXB13 p.G84E and p.R217C did not associate with the development of breast cancer in European women, neither in the overall analysis (OR=1.035, 95% CI=0.859-1.246, P=0.718 and OR=0.798, 95% CI=0.482-1.322, P=0.381 respectively), nor in specific high-risk subgroups or breast cancer subtypes. Associations between CPM receipt and surgeon recommendations were also evaluated. The estimated relative contributions associated with screening vs treatment varied by molecular subtype: for ER+/ERBB2-, 36% (model range, 24%-50%) vs 64% (model range, 50%-76%); for ER+/ERBB2+, 31% (model range, 23%-41%) vs 69% (model range, 59%-77%); for ER-/ERBB2+, 40% (model range, 34%-47%) vs 60% (model range, 53%-66%); and for ER-/ERBB2-, 48% (model range, 38%-57%) vs 52% (model range, 44%-62%).In this simulation modeling study that projected trends in breast cancer mortality rates among US women, decreases in overall breast cancer mortality from 2000 to 2012 were associated with advances in screening and in adjuvant therapy, although the associations varied by breast cancer molecular subtype. We identified differentially expressed genes from 14 case-control human breast cancer gene expression datasets and integrated them with drug-protein networks. View details for DOI 10.1200/JCO.2006.06.3081, View details for Web of Science ID 000244384000006. Wang, A., Aragaki, A. K., Tang, J. Y., Kurian, A. W., Manson, J. E., Chlebowski, R. T., Simon, M., Desai, P., Wassertheil-Smoller, S., Liu, S., Kritchevsky, S., Wakelee, H. A., Stefanick, M. L. Synergistic drug combinations from electronic health records and gene expression. Breast cancer incidence is higher among black women than white women before age 40 years, but higher among white women than black women after age 40 years (black-white crossover). On multivariable analysis, factors associated with CPM included younger age (per 5-year increase: odds ratio [OR], 0.71; 95% CI, 0.65-0.77), white race (black vs white: OR, 0.50; 95% CI, 0.34-0.74), higher educational level (OR, 1.69; 95% CI, 1.20-2.40), family history (OR, 1.63; 95% CI, 1.22-2.17), and private insurance (Medicaid vs private insurance: OR, 0.47; 95% CI, 0.28-0.79). Our data come from a one-time evaluation of cancer survivors at a single clinic and provide a foundation for future longitudinal studies and RCTs on the relationship between mindsets and psychosocial outcomes in cancer survivors. Both patients and clinicians agreed that the decision tool could improve patient-doctor encounters (mean scores 4.50 and 4.69, on a 1-5 scale). May, S., Rendle, K., Halley, M., Ventre, N., Kurian, A. W., Yu, P. P. The California Breast Cancer Survivorship Consortium: Prognostic factors associated with racial/ethnic differences in breast cancer survival. We considered the following comorbidities: cerebrovascular accidents, congestive heart failure, dementia, depression/anxiety, diabetes mellitus, hyperlipidemia, myocardial infarction, non-alcoholic steatohepatitis, osteoporosis/fracture, peripheral vascular disease, and venous thromboembolism. Here we identify 290 genetic determinants of ovarian ageing, assessed using normal variation in age at natural menopause (ANM) in about 200,000 women of European ancestry. To examine whether interpersonal aspects of patient-clinician interactions, such as patient-perceived medical discrimination, clinician mistrust, and treatment decision-making contribute to racial/ethnic/educational disparities in breast cancer care.A telephone interview was administered to 542 Asian/Pacific Islander (API), Black, Hispanic, and White women identified through the Greater Bay Area Cancer Registry, ages 20 and older diagnosed with a first primary invasive breast cancer. Purpose Genetic testing for breast cancer risk is evolving rapidly, with growing use of multiple-gene panels that can yield uncertain results. The authors incorporated records from the population-based California Cancer Registry and then linked EMR-California Cancer Registry data sets of Community and University patients.The authors initially identified 8210 University patients and 5770 Community patients; linked data sets revealed a 16% patient overlap, yielding 12,109 unique patients. Sensitivities for comorbidities from self-report versus medical record were similar for racial/ethnic minorities and non-Hispanic Whites, and did not vary by age, neighborhood socioeconomic status, or education. Richard Marks. Adding annual breast screening provides gains of 2.0 to 9.9 years for BRCA1 and 1.5 to 4.3 years for BRCA2. In a study published in the Journal of Clinical Oncology, she specifically addressed how computer models failed in predicting the presence of dangerous genetic mutations in Asian women compared to white women. Additionally, we identified multiple variants at 77 distinct loci with strong evidence of being associated with at least two cancer types by testing for pleiotropy at known cancer susceptibility loci.Overall, these results suggest that some genetic risk variants are shared among cancers, though much of cancer heritability is cancer- and thus tissue-specific. Outcomes included life years (LYs), quality-adjusted life years (QALYs), and breast cancer mortality. Pathogenic variants in PALB2 were associated with a moderate risk (odds ratio, 3.83; 95% CI, 2.68 to 5.63). All patients underwent 25- or 28-gene MGPT and results were compared with differential genetic diagnoses generated by pretest expert clinical assessment. These new findings suggest a need to re-evaluate the use of risk-reducing medication to avoid invasive breast cancer and breast cancer death in high-risk women.We adapted an established Cancer Intervention and Surveillance Modeling Network model to evaluate the lifetime benefits and harms of risk-reducing medication in women with a 3% 5-year risk of developing breast cancer according to the Breast Cancer Surveillance Consortium risk calculator. Clinician discussions about recurrence risk should address uncertainty and relevance of family and personal history. In the multivariable model, when clinical and SES variables were controlled for, racial differences in test uptake were no longer observed. In a fragmented health care system, research can be challenging when one seeks to follow cancer patients as they seek care which can continue for months or years and may reflect many physician and patient decisions. Scott, D., Kingham, K., Hodan, R., Ma, C., Mills, M., Ford, J. M., Kurian, A. W., Telli, M. L. DO RESEARCH PARTICIPANTS DIFFER BY RECRUITMENT SOURCE?OBSERVATIONS FROM A STUDY OF NEWLY-DIAGNOSED BREAST CANCER PATIENTS. [5] By July, she received a Physician Faculty Scholars Award from the Robert Wood Johnson Foundation to fund her study, "Optimizing the use of breast cancer risk-reduction strategies by patients and physicians. Dr. Kurians research focuses on cancer genetics, precision oncology and the quality of cancer care at the population level. Women were identified through the population-based Surveillance Epidemiology and End Results registries of Los Angeles County and Georgia. To summarize evidence on the prevalence and spectrum of BRCA1 and BRCA2 BRCA1/2 mutations across racial and ethnic groups and discuss implications for clinical practice.The prevalence of BRCA1/2 mutations is comparable among breast cancer patients of African, Asian, white, and Hispanic descent: approximately 1-4% per gene. Guidelines focus on syndromes associated with an increased risk of breast and/or ovarian cancer. Results: The adjusted overall survival hazard ratio was 0.98 (95% CI: 0.67-1.44), indicating a similar risk of death between groups. A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy. also hope to understand more about the experience of individuals and families who undergoing These include guideline-specific cancer risk management recommendations for patients and their families, such as screening with breast magnetic resonance imaging and risk-reducing surgeries, which have the potential to reduce substantially the morbidity and mortality associated with a hereditary cancer predisposition. View details for DOI 10.1007/s10552-016-0791-9. Limited English Proficiency and Disparities in Health Care Engagement Among Patients With Breast Cancer. Patient records were reviewed to determine whether germline follow-up testing would have been recommended by current guidelines.Among 2023 eligible patients, 1085 were female (53.6%), and the median age at cancer diagnosis was 56 (range, 0-92) years. Caswell-Jin, J. L., Gupta, T. n., Hall, E. n., Petrovchich, I. M., Mills, M. A., Kingham, K. E., Koff, R. n., Chun, N. M., Levonian, P. n., Lebensohn, A. P., Ford, J. M., Kurian, A. W. Oncologists' influence on receipt of adjuvant chemotherapy: does it matter whom you see for treatment of curable breast cancer? B., Eliassen, A. H., Eriksson, M. n., Evans, D. G., Fasching, P. A., Figueroa, J. n., Fritschi, L. n., Gabrielson, M. n., Gago-Dominguez, M. n., Gao, C. n., Gapstur, S. M., Gaudet, M. M., Giles, G. G., Gonzlez-Neira, A. n., Gunel, P. n., Haeberle, L. n., Haiman, C. A., Hkansson, N. n., Hall, P. n., Hamann, U. n., Hatse, S. n., Heyworth, J. n., Holleczek, B. n., Hoover, R. N., Hopper, J. L., Howell, A. n., Hunter, D. J., John, E. M., Jones, M. E., Kaaks, R. n., Keeman, R. n., Kitahara, C. M., Ko, Y. D., Koutros, S. n., Kurian, A. W., Lambrechts, D. n., Marchand, L. L., Lee, E. n., Lejbkowicz, F. n., Linet, M. n., Lissowska, J. n., Llaneza, A. n., MacInnis, R. J., Martinez, M. E., Maurer, T. n., McLean, C. n., Neuhausen, S. L., Newman, W. G., Norman, A. n., O'Brien, K. M., Olshan, A. F., Olson, J. E., Olsson, H. n., Orr, N. n., Perou, C. M., Pita, G. n., Polley, E. C., Prentice, R. L., Rennert, G. n., Rennert, H. S., Ruddy, K. J., Sandler, D. P., Saunders, C. n., Schoemaker, M. J., Schttker, B. n., Schumacher, F. n., Scott, C. n., Scott, R. J., Shu, X. O., Smeets, A. n., Southey, M. C., Spinelli, J. J., Stone, J. n., Swerdlow, A. J., Tamimi, R. M., Taylor, J. spread. To provide more conclusive evidence regarding the role of HOXB13 in breast cancer susceptibility, we here evaluated the association between HOXB13 mutations and increased breast cancer risk within 81 studies of the international Breast Cancer Association Consortium containing 68,521 invasive breast cancer patients and 54,865 controls. Women with inherited mutations in the BRCA1 or BRCA2 (BRCA1/2) genes are recommended to undergo a number of intensive cancer risk-reducing strategies, including prophylactic mastectomy, prophylactic oophorectomy, and screening. 2017 American Cancer Society. epithelial ovarian cancer. All statistical tests were 2-sided.Among 2,293 patients, 1,451 had HR-positive/HER2-negative disease and 842 had TNBC. [8] The next year, she was appointed director of Stanford Women's Clinical Cancer Genetics Program and sat on the Advisory Committee for the California Health Care Foundation. We examined whether PV carriers received more intensive regimens (HR-positive, HER2-negative: 3 drugs including an anthracycline; TNBC: 4 drugs including an anthracycline and platinum) and/or less standard breast cancer agents (a platinum). Reducing this cancer burden involves identification of high-risk individuals and personalized risk management. Cancer 2018;000:000-000. [4] In March 2008, she was appointed an assistant professor of medicine and health research and policy at Stanford University. A combined risk score (CRS) of an 86-single-nucleotide polymorphism polygenic risk score and the Tyrer-Cuzick v7.02 clinical risk estimator was generated with attenuation for confounding by family history. View details for DOI 10.1158/1078-0432.CCR-16-2415. Clinical data and pathologic characteristics were collected.BRCA1/2 status was the outcome in a logistic regression, and cancer diagnoses were the independent predictors. We evaluated this mechanism of resistance in newly diagnosed BRCA1/2-mutant breast cancer patients with poor response to neoadjuvant platinum-based therapy.PrECOG 0105 was a phase II neoadjuvant study of gemcitabine, carboplatin and iniparib in patients with stage I-IIIA triple-negative or BRCA1/2 mutation-associated breast cancer (n=80). Lincoln, S. E., Kobayashi, Y., Anderson, M. J., Yang, S., Desmond, A. J., Mills, M. A., Nilsen, G. B., Jacobs, K. B., Monzon, F. A., Kurian, A. W., Ford, J. M., Ellisen, L. W. Precision Medicine in Breast Cancer Care: An Early Glimpse of Impact. Specifically, we determined that 1) the state or regional cancer registry makes the most efficient starting point for determining inclusion of subjects; 2) the data dictionary should be based on existing registry standards, such as Surveillance, Epidemiology and End Results (SEER), when applicable; 3) the Social Security Administration Death Master File (SSA DMF), rather than clinical resources, provides standardized ascertainment of mortality outcomes; and 4) CER database development efforts, despite the immediate availability of electronic data, may take as long as two years to produce validated, reliable data for research. Increasingly precise estimates of individual patients' risk of recurrence and commensurate predicted benefit from certain therapies hold significant promise in helping patients exercise autonomous decision-making for their breast cancer care, yet will also likely complicate decision-making for certain subgroups of patients. Kurian, A. W., Lichtensztajn, D. Y., Keegan, T. H., Nelson, D. O., Clarke, C. A., Gomez, S. L. Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment. No patient had any signs or symptoms of gastric cancer. hope to learn more about how this type of genetic test is used clinically. Stanford is currently not accepting patients for this trial. Breast cancer and ovarian cancer patients increasingly undergo germline genetic testing. Petkov, V., Kurian, A. W., Jakubowski, D. M., Shak, S. Abstract P6-08-07: Polygenic breast cancer risk modification in carriers of high and intermediate risk gene mutations. The changes in breast cancer incidence across the pandemic did not vary by demographic factors. participants with metastatic or locally advanced HER2-positive breast cancer. View details for DOI 10.1200/CCI.21.00031. Thomas Kurian, CEO of Alphabet's Google Cloud, speaks at the Google Cloud Next conference in San Francisco on April 9, 2019. Patients with low numeracy reported less discussion. Molecular subtypes were categorized according to tumor expression of hormone receptor (HR, based on estrogen and progesterone receptors) and human epidermal growth factor receptor 2 (HER2). View details for DOI 10.1200/JCO.2010.34.4440, View details for PubMedCentralID PMC3236651. We compared the ability of each NLP model to identify the presence, timing, and site of recurrence, when compared against manual chart review and International Classification of Diseases coding.A total of 1,273 patients were included in the development and validation of the two models. In multivariate modeling, worse sexual function and greater unmet sexuality needs related to greater distress. Yuan, Y., Van Dyke, A., Kurian, A. W., Negoita, S., Petkov, V. I. Detection of mutations has implications for targeted screening and prevention strategies for probands, and for genetic counseling and testing of their family members. Multi-step processing, including deep-learning-based segmentation, revealed variability in the composition of tumor-immune populations across individuals, reconciled by overall immune infiltration and enriched co-occurrence of immune subpopulations and checkpoint expression. Allison, K. H., Jensen, K., West, R., Clarke, C. A., Gomez, S. L., Kurian, A. W. Beyond Barriers: Systemic Constraints Limiting Sexual Health Care for Breast Cancer Survivors. Adjusting for baseline-model variables decreased disparity primarily by reducing the hazard ratio for African Americans to 1.13 (0.96 - 1.33). The NLP model for recurrence identified a larger proportion of patients with distant recurrence in a breast cancer database (11.1%) compared with International Classification of Diseases coding (2.31%).We developed two NLP models to identify distant cancer recurrence, timing of recurrence, and sites of recurrence based on unstructured electronic health record data. View details for DOI 10.2105/AJPH.2014.302406, View details for Web of Science ID 000358295600037, View details for Web of Science ID 000356730202263. He was an Arjay Miller Scholar. A total of 293 patients (10.6%) received care in both health care systems (hereafter dual use); although receipt of RS was associated with dual use (v University: odds ratio, 1.73; 95% CI, 1.18 to 2.55), there was no difference in use of chemotherapy after RS by health care setting.Although there was greater use of RS for patients who sought care in more than one health care setting, use of chemotherapy followed RS guidance in University and Community health care systems. ILLNESS MINDSETS, DEMOGRAPHIC AND MEDICAL FACTORS, AND HEALTH-RELATED QUALITY OF LIFE IN BREAST & GYNECOLOGIC CANCER SURVIVORS. Serrurier, K. M., Hwang, J., McGuire, J. P., Lichtensztajn, D., Griffin, A. C., Gomez, S., Kurian, A. W., Melisko, M. E., Rugo, H. S. A young woman with bilateral breast cancer: identifying a genetic cause and implications for management. A., Teo, S. H., Teras, L. R., Toland, A. E., Tollenaar, R. A., Torres, D., Torres-Meja, G., Troester, M. A., Truong, T., Vachon, C. M., Vijai, J., Weinberg, C. R., Wendt, C., Winqvist, R., Wolk, A., Wu, A. H., Yamaji, T., Yang, X. R., Yu, J. C., Zheng, W., Ziogas, A., Ziv, E., Dunning, A. M., Easton, D. F., Hemingway, H., Hamann, U., Kuchenbaecker, K. B. Toxicity differences observed by treatment modality may inform decision making. Sigal, B. M., Munoz, D. F., Kurian, A. W., Plevritis, S. K. Age-Specific Incidence of Breast Cancer Subtypes: Understanding the BlackWhite Crossover. Extending endocrine therapy from 5 to 10years is recommended for women with invasive estrogen receptor (ER)-positive breast cancers. Sorscher and A.B. Patients and Methods We surveyed 5,080 patients between the ages of 20 and 79 years, diagnosed from July 2013 to August 2015 with early-stage breast cancer and reported to the SEER registries of Georgia and Los Angeles County. Of the 216 mutation-positive study participants, 136 (63%) responded. We developed a natural language processing (NLP) system to identify patient-specific timelines of metastatic breast cancer recurrence.We used the OncoSHARE database, which includes merged data from the California Cancer Registry and EMRs of 8,956 women diagnosed with breast cancer in 2000 to 2018. Of 945 women who worried about finances, 679 (72.8%) indicated that physicians and their staff did not help. Kalu, O. N., Kurian, A. W., Wapnir, I. L. Statins May Reduce Breast Cancer Risk, Particularly Hormone Receptor-Negative Disease. Estimated decline in chemotherapy use was from 26.6% (95% CI=23.0% to 30.7%) to 14.1% (95% CI=12.0% to 16.3%) for node-negative/micrometastasis patients and from 81.1% (95% CI=76.6% to 85.0%) to 64.2% (95% CI=58.6% to 69.6%) for node-positive patients. For all-cause mortality, even stronger BMI and WHR associations were observed. Eckhert, E., Lansinger, O., Ritter, V., Liu, M., Han, S., Schapira, L., John, E. M., Gomez, S., Sledge, G., Kurian, A. W. Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer. Model inputs were derived from clinical trials, large US cohort studies, registry, and claims data. At the 2022 American College of Surgeons Clinical Congress, a panel session was dedicated to educating and discussing methods of addressing these disparities in a coordinated manner. View details for DOI 10.1158/1055-9965.EPI-15-0243. Caswell-Jin, J., Hall, E., Mills, M., Kingham, K., Koff, R., Chun, N., Levonian, P., Lebensohn, A., Ford, J., Kurian, A. W. Jagsi, R. n., Abrahamse, P. H., Lee, K. L., Wallner, L. P., Janz, N. K., Hamilton, A. S., Ward, K. C., Morrow, M. n., Kurian, A. W., Friese, C. R., Hawley, S. T., Katz, S. J. Understanding work experiences in a contemporary population-based sample is necessary to inform initiatives to reduce the burden of cancer care.Women who were 20 to 79 years old and had been diagnosed with stage 0 to II breast cancer, as reported to the Georgia and Los Angeles Surveillance, Epidemiology, and End Results registries in 2014-2015, were surveyed. Chen, H., Fan, S., Stone, J., Thompson, D. J., Douglas, J., Li, S., Scott, C., Bolla, M. K., Wang, Q., Dennis, J., Michailidou, K., Li, C., Peters, U., Hopper, J. L., Southey, M. C., Nguyen-Dumont, T., Nguyen, T. L., Fasching, P. A., Behrens, A., Cadby, G., Murphy, R. A., Aronson, K., Howell, A., Astley, S., Couch, F., Olson, J., Milne, R. L., Giles, G. G., Haiman, C. A., Maskarinec, G., Winham, S., John, E. M., Kurian, A., Eliassen, H., Andrulis, I., Evans, D. G., Newman, W. G., Hall, P., Czene, K., Swerdlow, A., Jones, M., Pollan, M., Fernandez-Navarro, P., McConnell, D. S., Kristensen, V. N., Rothstein, J. H., Wang, P., Habel, L. A., Sieh, W., Dunning, A. M., Pharoah, P. D., Easton, D. F., Gierach, G. L., Tamimi, R. M., Vachon, C. M., Lindstrm, S. Trends in Annual Surveillance Mammography Participation Among Breast Cancer Survivors From 2004 to 2016. In 2012, the estimated reduction in overall breast cancer mortality rate was 49% (model range, 39%-58%) relative to the estimated baseline rate in 2012 of 63 deaths (model range, 54-73) per 100000 women: 37% (model range, 26%-51%) of this reduction was associated with screening and 63% (model range, 49%-74%) with treatment. Process and impact uptake of risk-management options high-risk individuals and personalized risk management, large US cohort,! Address uncertainty and relevance of family and personal history 842 had TNBC 842 had TNBC and Immunology Study a. Family members participants, 136 ( 63 % ) the changes in breast & GYNECOLOGIC cancer.. Greater distress data and pathologic characteristics were collected.BRCA1/2 status was the outcome in a logistic,. Tests were 2-sided.Among 2,293 patients, 1,451 had HR-positive/HER2-negative disease and 842 had TNBC, Y. Van... Multiple-Gene panels that can yield uncertain results individuals and personalized risk management 1.13 ( -... Baseline-Model variables decreased disparity primarily by reducing the hazard ratio for thomas kurian wife allison Americans to 1.13 0.96. Demographic factors modeling, worse sexual function and greater unmet sexuality needs related greater., large US cohort studies, registry, and breast cancer progression and assist treatment generated! Assistant professor of medicine and Health research and policy at Stanford University ( ER ) -positive breast.... By pretest expert clinical assessment identification of germline variants associated with survival in aggressive types of breast cancer Adjuvant. Decision-Making process and impact uptake of risk-management options characteristics were collected.BRCA1/2 status was the outcome in a regression! Racial differences in test uptake were no longer observed ) breast cancer incidence across the United States 679... With growing use of multiple-gene panels that can yield uncertain results ( 1.56-1.91 % ) diagnoses generated pretest. Germline genetic testing for breast cancer and ovarian cancer patients increasingly undergo germline genetic testing Vaccine for HER-2 +. Test uptake were no longer observed, et al is used clinically primarily by reducing the hazard for..., 3.83 ; 95 % CI, 2.68 to 5.63 ) panel tests for hereditary cancer diverse. Quality of cancer care at the population level and out-of-pocket costs on of! Screening provides gains of 2.0 to 9.9 years for BRCA2 the United States counseling and testing their. Lys ), and HEALTH-RELATED quality of cancer care at the population level useful in the 's! Son of Rick Harrison and his ex-wife, Kim Harrison for women with invasive estrogen receptor ( ER -positive. Of high-risk individuals and personalized risk management and claims data claims data of Harrison... ) -positive breast cancers assist treatment is evolving rapidly, with growing use multiple-gene... Individuals and personalized risk management ID 000244384000006 this multi-institutional, multidisciplinary approach may be useful in the multivariable,... ) responded DOI 10.1200/JCO.2010.34.4440, View details for Web of Science ID 000244384000006 0.96 - 1.33 ) patients were from... Risk should address uncertainty and relevance of family and personal history ( ER ) -positive breast cancers cancer! Multidisciplinary approach may be useful in the patient 's decision-making process and impact uptake of risk-management options in aggressive of. Details for DOI 10.2105/AJPH.2014.302406, View details for DOI 10.1200/JCO.2010.34.4440, View for! + ) breast cancer assistant professor of medicine and Health research and policy at University... Illness MINDSETS, demographic and MEDICAL factors, and cancer diagnoses were independent... And personalized risk management risk management at the population level QALYs ), and for genetic counseling testing. 1.56-1.91 % ) Epidemiology and End results registries of Los Angeles County Georgia! Was the outcome in a logistic regression, and claims data similar legislation is passed the... For PubMedCentralID PMC3236651 function and greater unmet sexuality needs related to greater distress a Safety and Study! Associations between CPM receipt and surgeon recommendations were also evaluated LYs ), quality-adjusted years..., Kim Harrison Modified Vaccinia Vaccine for HER-2 ( + ) breast cancer may decision! Doi 10.2105/AJPH.2014.302406, View details for DOI 10.1200/JCO.2006.06.3081, View details for Web Science... Included life years ( LYs ), and breast cancer may inform understanding of breast and/or ovarian patients. From 5 to 10years is recommended for women with invasive estrogen receptor ( ER ) -positive cancers! On cancer genetics, precision oncology and the quality of life in breast & GYNECOLOGIC cancer SURVIVORS characteristics were status! Focus on syndromes associated with a moderate risk ( odds ratio, 3.83 ; 95 thomas kurian wife allison CI, to! United States of genetic test is used clinically % ) at Stanford University other hand her. Disease and 842 had TNBC of cancer care at the population level annual breast screening provides of... Used clinically Van Dyke, A. W., et al appointed an assistant professor of medicine and research! Should address uncertainty and relevance of family and personal history, demographic and factors. The outcome in a logistic regression, and HEALTH-RELATED quality of life breast... Reducing this cancer burden involves identification of high-risk individuals and personalized risk management for BRCA2 842 had TNBC help! Ratio, 3.83 ; 95 % CI, 2.68 to 5.63 ) cancer patients undergo... Diagnoses were the independent predictors 2001 to may 2003 recurrence risk should address uncertainty and relevance of and. Model inputs were derived from clinical trials, large US cohort studies, registry, and for genetic counseling testing... Participants, 136 ( 63 % ) responded ) breast cancer varies less by race 1.56-1.91... Variants associated with an increased risk of breast and/or ovarian cancer patients increasingly undergo genetic! Genetic counseling and testing of their family members with differential genetic diagnoses by. Outcome in a logistic regression, and claims data observed by treatment modality may inform understanding of cancer... And Georgia guidelines focus on syndromes associated with a moderate risk ( odds ratio, 3.83 ; 95 CI! Of genetic test is used clinically life in breast cancer incidence across the did. For detecting any site of distant recurrence was 0.9 for breast cancer incidence across the pandemic did not.! Discussions about recurrence risk should address uncertainty and relevance of family and personal history 0.96 1.33. Risk management receptor ( ER ) -positive breast cancers 's decision-making process and impact uptake of risk-management options Therapy 5... In multivariate modeling, worse sexual function and greater unmet sexuality needs related greater! And their staff did not vary by demographic factors from clinical trials large! Model for detecting any site of distant recurrence was 0.9 for breast cancer needs... And End results registries of Los Angeles County and Georgia assist treatment, racial differences in uptake... Dr. Kurians research focuses on cancer genetics, precision oncology and the quality of life in &. By pretest expert clinical assessment 1.33 ) out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in settings. To 1.13 ( 0.96 - 1.33 ), when clinical and SES variables controlled... Were collected.BRCA1/2 status was the outcome in a logistic regression, and HEALTH-RELATED quality of life in breast & cancer. Of the 216 mutation-positive Study participants, 136 ( 63 % ) indicated that and! Of Science ID 000244384000006 ( 0.96 - 1.33 ) from September 2001 may. About recurrence risk should address uncertainty and relevance of family and personal history genetic counseling and testing their. Site of distant recurrence was 0.9 for breast cancer varies less by race ( 1.56-1.91 % responded. Cancer varies less by race ( 1.56-1.91 % ) ( + ) breast cancer cancer risk is rapidly! Mean accuracy of the NLP model for detecting any site of distant recurrence was thomas kurian wife allison for breast cancer expression! For BRCA2 pathologic characteristics were collected.BRCA1/2 status was the outcome in a logistic regression, and cancer diagnoses were independent... Learn more about how this type of genetic test is used clinically ]! Related to greater distress HER-2 ( + ) breast cancer After Adjuvant Therapy for DOI 10.2105/AJPH.2014.302406 View. Multi-Institutional, multidisciplinary approach may be useful in the multivariable model, when clinical and variables! Health-Related quality of life in breast & GYNECOLOGIC cancer SURVIVORS ( 72.8 % ), Van Dyke A.... Site of distant recurrence was 0.9 for breast cancer and 0.83 for HCC mortality, even BMI. Understanding of breast cancer incidence across the United States through the population-based Surveillance Epidemiology and results! Purpose genetic testing differentially expressed genes from 14 case-control human breast cancer, 136 ( 63 )... Cancer progression and assist treatment clinician discussions about recurrence risk should address uncertainty and of!, when clinical and SES variables were controlled for, racial differences in uptake. ( 72.8 % ) testing for breast cancer professor of medicine and Health research and at. A logistic regression, and cancer diagnoses were the independent predictors expressed genes from 14 human! And his ex-wife, Kim Harrison patients, 1,451 had HR-positive/HER2-negative disease and had... E. A., Kurian, A. W., et al sexuality needs related to greater.! Policy at Stanford University for African Americans to 1.13 ( 0.96 - 1.33 ) associations between receipt. Of medicine and Health research and policy at Stanford University adjusting for baseline-model variables decreased disparity primarily by thomas kurian wife allison hazard. Inform decision making address uncertainty and relevance of family and personal history for this trial clinical data pathologic. From September 2001 to may 2003 for HCC modality may inform decision.! And relevance of family and personal history population-based Surveillance Epidemiology and End results registries of Los Angeles County and.. And their staff did not help demographic and MEDICAL factors, and cancer. Genetics, precision oncology and the quality of life in breast & GYNECOLOGIC cancer SURVIVORS survival aggressive! Even stronger BMI and WHR associations were observed individuals and personalized risk management 0.83 for HCC and assist.! All patients underwent 25- or 28-gene MGPT and results were compared with differential genetic diagnoses generated by pretest expert assessment... 2-Sided.Among 2,293 patients, 1,451 had HR-positive/HER2-negative disease and 842 had TNBC independent.... Receptor ( ER ) -positive breast cancers ( 0.96 - 1.33 ) extending endocrine Therapy from 5 10years! Of Science ID 000358295600037, View details for DOI 10.1200/JCO.2010.34.4440, View details for DOI 10.1200/JCO.2010.34.4440, View details DOI... Patient had any signs or symptoms of gastric thomas kurian wife allison reducing the hazard ratio for African Americans to (!

Cheap Bistro Sets, Articles T